Introduction
============

The release of Ca^2+^ from stores of the sarcoplasmic reticulum (SR) stimulates contraction of striated muscle fibers through ATP hydrolysis coupled to induced conformational changes of the actin-myosin protein complex. In 1994, we discovered that the known bromotyrosine tetramer, bastadin-5 (**1**)\[[@b1-marinedrugs-02-00176]\] from the marine sponge *Ianthella basta* (Pallas), is a potent modulator of Ca^2+^ release from the SR\[[@b2-marinedrugs-02-00176]\]. Bastadin-5 stimulates release of Ca^2+^ from the SR by binding to the RyR1-FKBP12 Ca^2+^ channel, a tetrameric heterodimeric channel protein (\~2000 kDa) that is associated with the smaller 12 kDa immunophilin FKBP12 \[[@b3-marinedrugs-02-00176]\]. The mechanism of action of **1** is not fully understood, but it is known that binding occurs at a site on the SR junctional protein that is distinct from those of known effector molecules, including ATP and caffeine \[[@b2-marinedrugs-02-00176]\]. Bastadin-5 and -10 \[[@b4-marinedrugs-02-00176]\] also have been shown to relate ryanodine-sensitive and -insensitive Ca^2+^ efflux pathways in skeletal SR and BC~3~H1 cells \[[@b5-marinedrugs-02-00176]\]. Recently, we took the opportunity to examine the most polar fractions from extracts of the sponge *Ianthella basta*, collected in Guam, and found a complex mixture of bastadin *O*-sulfate esters from which we have isolated the new compounds 1-*O*-sulfatohemibastadin-1 (**2**) and 1-*O*-sulfatohemibastadin-2 (**3**), along with the known compound 32-*O*-sulfatobastadin-13 (**4**) \[[@b11-marinedrugs-02-00176]\] and a third new compound, the bastadin sulfate ester 34-*O*-sulfatobastadin-9 (**5**), The structures of the new compounds were established by interpretation of their spectral data and comparison with the parent phenols \[[@b6-marinedrugs-02-00176]\]. To our surprise, **2** and **3** exhibited *antagonistic* activity toward the RyR-1/FKBP12 complex (IC~50~ 13 and 29 μM, respectively). This is the first report of antagonism of the SR channel by a bastadin analog, and suggests a bimodal mechanism of action upon a common, but as-yet unidentified, effector site of the RyR1-FKBP12 channel complex.
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Results and Discussion
======================

Samples of freshly collected *Ianthella basta* (Pallas) were directly extracted in solvent (1:1 CH~2~Cl~2~-MeOH) and the concentrated extracts purified by silica flash chromatography using a gradient of MeOH in CH~2~Cl~2~. Pooled extracts that eluted with 3:1 CH~2~Cl~2~-MeOH were further purified by HPLC (reversed phase, C~18~, MeOH-H~2~O followed by C~18~, 70:30:0.05 H~2~O-CH~3~CN-TFA) to provide two new sulfated hemibastadins, **2** and **3**, the known **4**\[[@b11-marinedrugs-02-00176]\] and the novel 34-*O*-sulfatobastadin-9 (**5**). All compounds were readily soluble in MeOH and appreciably soluble in water, but insoluble in CHCl~3~.

Detailed MS analysis was used to secure compositions of the new compounds. For the purpose of clarity in the description that follows M is defined as the neutral acid, but the structures are depicted, here, as the Na^+^ salts of the sulfate half-esters. MALDI HRMS of **2** (*m/z* 594.8815 \[M-H+2Na\]^+^ Δ mmu +6.0) showed the presence of two Br atoms and secured the formula of the neutral compound as C~17~H~16~Br~2~N~2~O~7~S, which suggested a structure of almost half the molecular mass of the macrocyclic bastadins (e.g. **1**\[[@b7-marinedrugs-02-00176]\]). Fragment ions in the ESI mass spectrum of **2** due to loss of SO~3~ implicated the presence of *O*-sulfate esters. The ^1^H- and ^13^C-NMR spectra of **2**, although displaying similar chemical shifts and couplings as those of bastadin-5 \[[@b8-marinedrugs-02-00176]\], contained about half of the expected signals of the macrodilactams ([Table 1](#t1-marinedrugs-02-00176){ref-type="table"}). Lack of mirror symmetry in the NMR spectra, together with signals that accounted for a 3-bromo-4-tyramine and oxime-modified 3-bromotyrosine units suggested a 'hemibastadin' similar to the compounds from another sample of *I. basta* described by Capon and coworkers \[[@b6-marinedrugs-02-00176]\]. The configuration of the ketoxime group in **2** was *E*, as is usually found in this series of compounds \[[@b9-marinedrugs-02-00176]\]. ^1^H-^13^C correlations observed in the HSQC and HMBC spectra of **2** were fully compatible with the proposed structure, including the position of the *O*-SO~3~H group which was assigned as follows. The ^13^C-NMR signals of phenols undergo well-described local changes in δ upon *O*-sulfation. Ragan has documented that the *ipso* carbon of a phenol undergoes a diamagnetic shift (Δδ −2.8\~5.0 ppm upfield) while the *ortho* carbon signals suffer downfield shifts (Δδ +6.3--7.8 ppm) upon substitution of OH for O(SO~3~H) or the corresponding alkali metal salt O(SO~3~M)\[[@b10-marinedrugs-02-00176]\]. For example, changes in ^13^C shifts were used to place the *O*-sulfate esters in 34-*O*-sulfatobastadin-1 \[[@b11-marinedrugs-02-00176]\], 15,34-*O*-di-sulfatobastadin-7 and **4**\[[@b8-marinedrugs-02-00176]\].

Critical ^13^C-NMR assignments that distinguished the signals of the two aryl rings were made on the basis of HMBC and nOe experiments ([Figure 1](#f1-marinedrugs-02-00176){ref-type="fig"}). Because the substitution pattern in each trisubstituted phenyl ring of **2** was the same, we could simply compare the assigned ^13^C-NMR signals in each ring to determine which phenoxyl group was esterified as a sulfate ester.

The *O*-substituted *para-*carbon of the bromotyramine ring in **2** showed an upfield shift of the C1 ^13^C signal in **2** (δ 149.7, s), with respect to the corresponding signal in the bromotyrosine ring at C1' (δ 153.8 s) \[[@b12-marinedrugs-02-00176]\]. Conversely, the *ortho*^13^C-NMR signals of C2 (δ 116.7, s) and C6 (δ 123.4, d) were displaced in the paramagnetic direction (c.f. δ 110.5, s, C2'; 117.1, d, C6'). Thus, the O(SO~3~H) group is located at C1 of the 3-bromotyramine ring.

Obtaining reliable positive ion ESI and MALDI mass spectra of **3** was made difficult by the tendency of the compound to form dimers and trimers under standard conditions. Negative ion ESIMS, which gave better results with **3** and other bastadins, revealed discrete ions due to \[M-H\]^−^ (*m/z* 627) and \[M-2H+Na\]^−^ (*m/z* 649) and a 1:3:3:1 isotope pattern indicating three Br atoms. Eventually, positive ion MALDI HRMS provided a reliable pseudomolecular ion (\[M--H+2Na\]^+^*m/z* 672.7899, Δ+1.8 mmu) corresponding to the formula M of **3**, C~17~H~15~Br~3~N~2~O~7~S. ^1^H-NMR showed replacement of one set of aryl ring signals with a two-proton singlet (δ 7.38, s, 2H) and simplification of the ^13^C-NMR spins to four signals indicating a local mirror plane of symmetry. Thus, compound **3** is a sulfate ester of hemibastadin-2 \[[@b6-marinedrugs-02-00176]\]. The O(SO~3~H) group was again located at C1 employing arguments similar to those used for **2**.

The ESI mass spectrum of **5** showed an isotope pattern corresponding to the presence of four Br atoms and loss of SO~3~ that indicated the presence of a sulfate half ester. The formula C~34~H~27~Br~4~N~4~O~11~SNa~2~ for compound **5**, (MALDI HRMS, *m/z* 1060.7840 \[M--H+2Na\]^+^ Δmmu = −8.6) was isomeric with the known sodium salt of 34-*O*-sulfatobastadin-13 (**6**) \[[@b11-marinedrugs-02-00176]\]. The ^1^H-NMR spectrum of **5** (*d*~6~-DMSO) revealed spin systems corresponding to four benzene rings; two trisubstituted, one tetrasubstituted and a 3,5-dibromo-4-phenoxyl ring (phenol numbering, δ 7.55, s, 2H, H28,30) that was identified from the presence of a local plane of symmetry (C1,4 axis). Exchangeable proton signals were observed for the two oxime groups (δ 11.87, s; 11.71, s), however, only one phenolic OH was evident (δ 9.30, s) which supported a phenolic *O*-sulfate ester. Consideration of the four possible parent bastadin skeleta that are isomeric with the parent of **5** (bastadin-9 \[[@b4-marinedrugs-02-00176]\], bastadin-13 \[[@b6-marinedrugs-02-00176]\], bastadin-18 \[[@b13-marinedrugs-02-00176]\] and bastadin-20 \[[@b8-marinedrugs-02-00176]\] allowed us to eliminate the latter two structures based on their lack of a symmetrically substituted 3,5-dibromobenzene ring. 34-*O*-Sulfatobastadin-13 (**6**) has been characterized by Wright and co-workers \[[@b11-marinedrugs-02-00176]\], however the ^1^H-NMR data for this compound differed considerably from those of **5** (both recorded in *d*~6~-DMSO). For example, the isochronous proton pair H27/31 in **5** resonated at lower field (δ 7.55, 2H) than **6** (δ 7.42, s, 2H \[[@b11-marinedrugs-02-00176]\]) and the exceptionally high field aryl doublet in **5** (δ 6.20, d, *J*= 2.0 Hz) is not found in **6** (the closest signal is H-8, δ 6.50, d, *J*= 2.0 Hz). The exclusion of **6** leaves only three undescribed isomers -- 10-*O*-sulfatobastadin-13, 10-*O*-sulfatobastadin-9 and 34-*O*-sulfato- bastadin-9 -- as remaining possibilities. The former two are eliminated because compound **5** lacks the downfield shifted ^1^H-NMR signal expected for an H-11 or H-16 proton *ortho* to an *O*-sulfate ester (Δδ\~ −0.7 ppm, c.f. **2**). Thus, we tentatively assigned the structure 34-*O*-sulfatobastadin-9 to **5**. Unfortunately, limited sample precluded acquisition of a complete ^13^C-NMR spectrum, however, a partial set of HMBC correlations observed for **5** were consistent with the proposed structure.
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Compounds **1--3** were assayed for binding of \[^3^H\]-ryanodine to the high-affinity site of the ryanodine receptor in the RyR1-FKBP12 complex \[[@b15-marinedrugs-02-00176], [@b2-marinedrugs-02-00176]\]. Ryanodine binding is an indicator of the 'open state' of the SR Ca^2+^ channel. Bastadin-5 (**1**) showed the expected stimulation of ryanodine binding to the channel in the open state (EC~50~ 2 μM) \[[@b2-marinedrugs-02-00176]\], however, both compounds **2** and **3** were antagonists and *inhibited* binding of \[^3^H\]-ryanodine (IC~50~ 13 μM and 29 μM, respectively). This contrasts with 15,34-*O*-di-sulfatobastadin-7 and **4** which are weak agonists of the receptor (EC~50~ 13.6 μM and 100 μM, respectively) \[[@b8-marinedrugs-02-00176]\]. Given the similarity of the structures of **2** and **3** and their resemblance to a 'truncated' northern hemisphere of **1**, it is likely that all three compounds interact with the same site, however, the mode of action with respect to Ca^2+^ channel opening are clearly distinct. Further investigations of these phenomena aimed at refinement of a model for bastadin-5-promoted Ca^2+^ release are underway in our laboratories.

Conclusions
===========

Two new hemibastadin sulfate esters isolated from *Ianthella basta* were characterized. The compounds suppressed ryanodine binding with IC~50~'s 13 μM and 29 μM, respectively. This is the *opposite* effect of bastadin-5 (**1**), a potent agonist of Ca^2+^ release from the SR. Although **1--3** have structural features in common, and most likely a common binding motif, the mode of action suggests **2** and **3** inhibit channel opening. Thus, a broader structure-relationship emerges for bastadins that reveals a bimodal mechanism of action.

Experimental
============

General
-------

NMR spectra were obtained using either Varian Inova 400 NMR or a Bruker DRX-600 spectrometer (equipped with a cryoprobe) operating at 399.771 MHz or 600.304 MHz for ^1^H and 100.531 MHz for ^13^C. Solvents used in extraction or chromatography were HPLC-grade or distilled from glass. ESIMS was carried out on a ThermoFinnigan Surveyor HPLC and LC Deca ion-trap by infusion in MeOH solution (0.1% HCOOH). HRMS measurements were provided by the University of California, Riverside Mass Spectrometry Facility. Other experimental procedures are described elsewhere \[[@b14-marinedrugs-02-00176]\].

Isolation of **1--5**
---------------------

The sponge *Ianthella basta* (Pallas) was collected by hand (2002) using scuba in Mangilao, Guam, and immediately steeped in CH~2~Cl~2~-MeOH. The organic extract was filtered and the filtrate concentrated to give a deep red gum. A portion of the extract (3.20 g) was dissolved in 1:1 CH~2~Cl~2~-MeOH and the solution combined silica (ca. 1g silica/100 mg) and concentrated to remove the solvent. The dry silica was slurried in CH~2~Cl~2~ and loaded onto the top of a silica column packed with CH~2~Cl~2~ and the column eluted with a gradient of MeOH in CH~2~Cl~2~. The fraction eluting with 3:1 CH~2~Cl~2~-MeOH was further separated by HPLC (reversed phase C~18~, Dynamax 10×250 mm, 60:40 H~2~O-MeOH, 3.0 mL/min) and the eluates monitored with a UV detector (λ 254 nm) to afford two fractions: 'a' (51.0 mg, *t*~R~ = 5 min) and 'b' (111.7 mg, *t*~R~ = 6.5 min). Purification of fraction 'a' on HPLC (RP C~18~, Dynamax 10 × 250 mm, 70:30:0.05 H~2~O-CH~3~CN-TFA, 4.0 mL/min) gave 1-*O*-sulfatohemibastadin-1 (**2**, 5.2 mg, *t*~R~ = 6.5), 1-*O*-sulfatohemibastadin-2 (**3**, 7.3 mg, *t*~R~ = 8 min), **5** (8.0 mg, *t*~R~ =16 min), and **4**\[[@b8-marinedrugs-02-00176]\] (23.4 mg, *t*~R~ = 18 min).

Spectroscopic Data
------------------

*1-O-Sulfatohemibastadin-1* (**2**): colorless solid; ^1^H-NMR and ^13^C-NMR (CD~3~OD): see [Table 1](#t1-marinedrugs-02-00176){ref-type="table"}; MALDI HRMS m/z 594.8815 \[M-H+2Na\]^+^; calcd. 594.8762 for C~17~H~15\ 79~Br~2~N~2~O~7~SNa~2~.

*1-O-Sulfatohemibastadin-2* (**3**): colorless solid; UV (MeOH): λ~max~ 204, 282 nm; IR (film) ν 3363 bs, 1678 s, 1211 s, 1145 cm^−1;\ 1^H-NMR and ^13^C-NMR (CD~3~OD): see [Table 1](#t1-marinedrugs-02-00176){ref-type="table"}; LR ESIMS (-ve ion) *m/z* 649 \[M--2H+Na\]^−^, 627 \[M-H\]^−^; MALDI HRMS (+ve ion) *m/z* 672.7899 \[M--H+2Na\]^+^; calcd. 672.7862 for C~17~H~14\ 79~Br~3~N~2~O~7~SNa~2~.

*34-O-Sulfatobastadin-9* (**5**): colorless solid; ^1^H-NMR (*d*~6~-DMSO) 11.87 (s, 1H, N-OH), 11.71 (s, 1H, N-OH), 9.33 (s, 1H, Ar-OH), 7.98 (t, *J*= 5.6 Hz, 1H, NH), 7.95 (t, *J*= 5.6 Hz, 1H, NH), 7.55 (s, 2H, H28/30), 7.49 (d, *J*=2.0 Hz, 1H), 7.11 (dd, *J*= 8.4, 2.0 Hz, 1H), 7.09 (d, *J*= 2.0 Hz, 1H), 6.84 (d, *J*= 8.4 Hz, 1H), 6.81 (dd, *J*= 8.4, 2.0 Hz, 1H), 6.75 (d, *J*=8.4 Hz, 1H), 6.71 (d, *J*= 2.0 Hz, 1H), 6.20 (d, *J*= 2.0 Hz, 1H), 3.58 (s, 2H), 3.53 (s, 2H), 3.41 (m, 2H), 3.21 (m, 2H), 2.66 (t, *J*= 7.2 Hz, 2H), 2.62 (t, *J*=7.2 Hz, 2H). MALDI HRMS *m/z* 1060.7840 \[M--H+2Na\]^+^; calcd. C~34~H~27\ 79~Br~4~N~4~O~11~SNa~2~ 1060.7920.

\[^3^H\]-Ryanodine Binding Assay
--------------------------------

Specific binding of \[^3^H\]-ryanodine to high affinity sites on rabbit skeletal membrane vesicles \[[@b2-marinedrugs-02-00176],[@b15-marinedrugs-02-00176]\] was determined by incubating SR protein (25 μg), containing the RyR1-FKBP12 complex, with \[^3^H\]ryanodine (1 nM) for 3.5 h at 37° C in binding assay buffer containing KCl (250 mM), NaCl (15mM), HEPES (20 mM), CaCl~2~ (20 μM) and at pH 7.4 (500 μL, final volume). The binding reaction was initiated by addition of the drug in DMSO (final DMSO conc. \~1%) to the complete assay medium and the incubation was terminated by filtration through Whatman GF/B glass fiber filters using a Brandel cell harvester (Gaithersburg, MD). Separation of bound and free \[^3^H\]-ryanodine was performed by washing the filters with ice-cold buffer (3 × 500 μL) containing Tris-HCl (20 mM), KCl (250 mM), NaCl (15 mM) at pH 7.4. Filters were placed in scintillation vials containing scintillant (5 mL). Bound radioactivity was measured by scintillation counting and corrected for background. Positive controls were bastadin-5 (EC~50~ 2.0 μM) and PCB95 (2,2′,3,5′,6-pentachlorobiphenyl)\[[@b16-marinedrugs-02-00176]\] and nonspecific binding was determined in the presence of 100-fold unlabeled ryanodine.
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###### 

^1^H-NMR (400 MHz) and ^13^C-NMR (100 MHz) data for **2** and **3**[a](#tfn1-marinedrugs-02-00176){ref-type="table-fn"}

  *\#*                                                     ^13^C-NMR (**2**), δ   ^1^H-NMR (**2**) δ (mult., *J* Hz, Int.)   HMBC         ^13^C-NMR (**3**) δ   ^1^H-NMR (**3**) δ (mult., *J* Hz, Int.)   HMBC
  -------------------------------------------------------- ---------------------- ------------------------------------------ ------------ --------------------- ------------------------------------------ ----------
  1[b](#tfn2-marinedrugs-02-00176){ref-type="table-fn"}    149.7                                                             H3, H5, H6   149.8                                                            
  2                                                        116.7                                                             H3, H6       116.7                                                            
  3                                                        134.5                  7.42 (d, *J*=2.0, 1H)                      H5, H7       134.5                 7.42 (d, *J*=2.0, 1H)                      \-
  4                                                        138.5                                                             H6, H7, H8   138.5                                                            H7, H8
  5                                                        129.7                  7.09 (dd, *J*=8.4,2.0, 1H)                 H3, H7       129.7                 7.11 (dd, *J*=8.4,2.0, 1H)                 H7
  6                                                        123.4                  7.49 (d, *J*=8.4, 1H)                                   123.5                 7.50 (d, *J*=8.4, 1H)                      
  7                                                        35.4                   2.75 (t, *J*=7.2, 2H)                      H3, H5, H8   35.4                  2.76 (t, 2H, *J*=7.2)                      H8
  8                                                        41.7                   3.43 (t, *J*=7.2, 2H)                      H7           41.8                  3.43 (t, 2H, *J*=7.2)                      H7
  1′[b](#tfn2-marinedrugs-02-00176){ref-type="table-fn"}   153.8                                                             H3′, H5′     150.7                                                            H3′, H5′
  2′                                                       110.5                                                             H3′, H6′     112.0                                                            H3′
  3′                                                       134.5                  7.36 (d, *J*=2.0, 1H)                      H5′, H7′     133.9                 7.38 (s, 2H)                               H7′
  4′                                                       130.6                                                             H6′, H7′     132.3                                                            H7′
  5′                                                       130.2                  7.02 (dd, *J*=8.0, 2.0, 1H)                H3′, H7′     133.9                 7.38 (s, 2H)                               H7′
  6′                                                       117.1                  6.76 (d, *J*=8.0, 1H)                      112.0                                                                         H5′
  7′                                                       28.6                   3.78 (s, 2H)                               H3′, H5′     28.4                  3.78 (s, 1H)                               H3′, H5′
  8′                                                       153.2                                                             H7′          152.5                                                            H7′
  9′                                                       165.8                                                             H7′, H8      165.6                                                            H8, H7′

^1^H-NMR chemical shifts recorded in CD~3~OD (99.5% atom D) are referenced to the residual solvent proton signal, δ 3.30 ppm. ^1^H- assignments are based on COSY, HSQC and chemical shift considerations;

The carbon chemical shifts of C1 and C1' (--OSO~3~H vs.-OH) were assigned based on the expected *upfield*^13^C- shift of the *ipso* carbon upon sulfation of the OH (Ragan, \[[@b10-marinedrugs-02-00176]\]).
